First successful treatment of pediatric high-risk refractory neuroblastoma with PARP inhibition
Scientists and clinicians at St. Jude Children’s Research Hospital identified the genetic vulnerability BARD1 in a patient with pediatric neuroblastoma, successfully treating the disease with targeted therapy.
Comentarios